420 related articles for article (PubMed ID: 26485709)
1. Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells.
Acikgoz E; Guven U; Duzagac F; Uslu R; Kara M; Soner BC; Oktem G
PLoS One; 2015; 10(10):e0141090. PubMed ID: 26485709
[TBL] [Abstract][Full Text] [Related]
2. Phenethyl isothiocyanate (PEITC) promotes G2/M phase arrest via p53 expression and induces apoptosis through caspase- and mitochondria-dependent signaling pathways in human prostate cancer DU 145 cells.
Tang NY; Huang YT; Yu CS; Ko YC; Wu SH; Ji BC; Yang JS; Yang JL; Hsia TC; Chen YY; Chung JG
Anticancer Res; 2011 May; 31(5):1691-702. PubMed ID: 21617228
[TBL] [Abstract][Full Text] [Related]
3. A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells.
Atmaca H; Bozkurt E; Uzunoglu S; Uslu R; Karaca B
Toxicol Lett; 2013 Aug; 221(2):128-36. PubMed ID: 23792433
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells.
Atmaca H; Uzunoglu S
Eur Cytokine Netw; 2014 Mar; 25(1):1-7. PubMed ID: 24941346
[TBL] [Abstract][Full Text] [Related]
5. In vitro radiosensitisation by trabectedin in human cancer cell lines.
Romero J; Zapata I; Córdoba S; Jimeno JM; López-Martín JA; Tercero JC; De La Torre A; Vargas JA; Molerón R; Sánchez-Prieto R
Eur J Cancer; 2008 Aug; 44(12):1726-33. PubMed ID: 18501589
[TBL] [Abstract][Full Text] [Related]
6. Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol.
Soner BC; Aktug H; Acikgoz E; Duzagac F; Guven U; Ayla S; Cal C; Oktem G
Int J Mol Med; 2014 Nov; 34(5):1249-56. PubMed ID: 25216351
[TBL] [Abstract][Full Text] [Related]
7. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.
Suy S; Mitchell JB; Samuni A; Mueller S; Kasid U
Cancer; 2005 Mar; 103(6):1302-13. PubMed ID: 15685617
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human prostate cancer (PC-3) cells and targeting of PC-3-derived prostate cancer stem cells with koenimbin, a natural dietary compound from
Kamalidehghan B; Ghafouri-Fard S; Motevaseli E; Ahmadipour F
Drug Des Devel Ther; 2018; 12():1119-1133. PubMed ID: 29765202
[TBL] [Abstract][Full Text] [Related]
9. SRJ23, a new semisynthetic andrographolide derivative: in vitro growth inhibition and mechanisms of cell cycle arrest and apoptosis in prostate cancer cells.
Wong HC; Wong CC; Sagineedu SR; Loke SC; Lajis NH; Stanslas J
Cell Biol Toxicol; 2014 Oct; 30(5):269-88. PubMed ID: 25070834
[TBL] [Abstract][Full Text] [Related]
10. Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3.
Kan SF; Yu CH; Pu HF; Hsu JM; Chen MJ; Wang PS
J Cell Biochem; 2007 May; 101(1):44-56. PubMed ID: 17340628
[TBL] [Abstract][Full Text] [Related]
11. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer.
Qadan LR; Perez-Stable CM; Anderson C; D'Ippolito G; Herron A; Howard GA; Roos BA
Biochem Biophys Res Commun; 2001 Aug; 285(5):1259-66. PubMed ID: 11478793
[TBL] [Abstract][Full Text] [Related]
12. Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair.
Harnicek D; Kampmann E; Lauber K; Hennel R; Cardoso Martins AS; Guo Y; Belka C; Mörtl S; Gallmeier E; Kanaar R; Mansmann U; Hucl T; Lindner LH; Hiddemann W; Issels RD
Int J Cancer; 2016 Jul; 139(2):467-79. PubMed ID: 26933761
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.
Tavecchio M; Natoli C; Ubezio P; Erba E; D'Incalci M
Cell Prolif; 2007 Dec; 40(6):885-904. PubMed ID: 18021177
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
[TBL] [Abstract][Full Text] [Related]
15. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
Aranha O; Grignon R; Fernandes N; McDonnell TJ; Wood DP; Sarkar FH
Int J Oncol; 2003 Apr; 22(4):787-94. PubMed ID: 12632069
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid overcomes chemoresistance by sensitizing cancer stem cells to apoptosis.
Rouhrazi H; Turgan N; Oktem G
Biotech Histochem; 2018; 93(2):77-88. PubMed ID: 29300112
[TBL] [Abstract][Full Text] [Related]
17. Berberis libanotica Ehrenb extract shows anti-neoplastic effects on prostate cancer stem/progenitor cells.
El-Merahbi R; Liu YN; Eid A; Daoud G; Hosry L; Monzer A; Mouhieddine TH; Hamade A; Najjar F; Abou-Kheir W
PLoS One; 2014; 9(11):e112453. PubMed ID: 25380390
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
19. Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action.
Martínez-Serra J; Maffiotte E; Martín J; Bex T; Navarro-Palou M; Ros T; Plazas JM; Vögler O; Gutiérrez A; Amat JC; Ramos R; Saus C; Ginés J; Alemany R; Diaz M; Besalduch J
Eur J Pharmacol; 2011 May; 658(2-3):57-64. PubMed ID: 21371453
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma.
Nakai T; Imura Y; Tamiya H; Yamada S; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
Cancer Med; 2017 Sep; 6(9):2121-2130. PubMed ID: 28745431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
